David A. Eichenbaum, MD

  The FDA approved Encelto, an encapsulated cell therapy, for the treatment of macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.

CHICAGO — In this Healio Video Perspective from the AAO meeting, David A. Eichenbaum, MD, discusses results from a phase 1 trial investigating axitinib for the treatment of neovascular age-related macular degeneration.

In this Healio Video Perspective from the Retina Society meeting, David A. Eichenbaum, MD, of Retina Vitreous Associates of Florida, presents promising 12-month results from the DAVIO 2 trial.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, David A. Eichenbaum, MD, presents real-world data related to the use of aflibercept 8 mg.

The FDA granted de novo marketing authorization to Notal Vision for the patient self-operated AI-powered Scanly Home OCT device, according to a press release.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, David A. Eichenbaum, MD, discusses the design of phase 3 trials of sozinibercept for the treatment of neovascular age-related macular degeneration.

In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, David A. Eichenbaum, MD, discusses data on ABBV-RGX-314 for neovascular age-related macular degeneration.

WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, David A. Eichenbaum, MD, discusses the potential for gene therapy to reduce the intravitreal injection treatment burden in retinal disease.

In this Healio Video Perspective, David A. Eichenbaum, MD, discusses data presented at the Retina Society meeting that looked at angiography and macular leakage in patients with diabetic macular edema.

An aflibercept biosimilar demonstrated positive results in the treatment of wet age-related macular degeneration in a phase 3 study, according to a press release from Sandoz.